Human Gene Set: SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_HIGH
_VS_LOW_RESPONDERS_MEDIUM_HIGH_ADVERSE
_EVENTS_SCORE_1DY_TRANSIENT_UP

Standard name

SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_HIGH_VS_LOW_RESPONDERS_MEDIUM_HIGH_ADVERSE_EVENTS_SCORE_1DY_TRANSIENT_UP

Systematic name

M41060

Brief description

Genes up-regulated in peripheral blood mononuclear cell high vs low responders in adults (18-64) (medium-high adverse events score) after exposure to Pandemrix , time point 1D. Comment: High AE individuals show day +1 and pre-vaccine differences to asymptomatic study subjects. (e) Genes expressed differentially in low AE vs medium/high AE study subjects on post-vaccine day +1

Full description or abstract

Adjuvanted vaccines afford invaluable protection against disease, and the molecular and cellular changes they induce offer direct insight into human immunobiology. Here we show that within 24 h of receiving adjuvanted swine flu vaccine, healthy individuals made expansive, complex molecular and cellular responses that included overt lymphoid as well as myeloid contributions. Unexpectedly, this early response was subtly but significantly different in people older than ~35 years. Wide-ranging adverse clinical events can seriously confound vaccine adoption, but whether there are immunological correlates of these is unknown. Here we identify a molecular signature of adverse events that was commonly associated with an existing B cell phenotype. Thus immunophenotypic variation among healthy humans may be manifest in complex pathophysiological responses.

Collection

C7: Immunologic Signature
VAX: HIPC Vaccine Response

Source publication

Pubmed 26726811 Authors: Sobolev O,Binda E,O'Farrell S,Lorenc A,Pradines J,Huang Y,Duffner J,Schulz R,Cason J,Zambon M,Malim MH,Peakman M,Cope A,Capila I,Kaundinya GV,Hayday AC

Exact source

Fig 5e

Related gene sets